The role of glycogen synthase kinase-3 in insulin resistance and Type 2 diabetes

Oksana Kaidanovich, Hagit Eldar-Finkelman*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

106 Scopus citations


Glycogen synthase kinase-3 (GSK-3) is a ubiquitous cytosolic serine/threonine protein kinase that has been implicated in multiple receptor-mediated intracellular processes. Its unique feature, which distinguishes it from other protein kinases, is that it is constitutively active in resting conditions and acts as a suppressor of signalling pathways. The fact that the function of two key targets of insulin action, glycogen synthase and insulin receptor substrate-1, are suppressed by GSK-3, as well as the fact that GSK-3 activity is higher in diabetic tissues, makes it a promising drug discovery target for insulin resistance and Type 2 diabetes. Thus, the development of GSK-3 inhibitors has received attention as an attempt to control both the spread of the disease and its severity.

Original languageEnglish
Pages (from-to)555-561
Number of pages7
JournalExpert Opinion on Therapeutic Targets
Issue number5
StatePublished - 2002


  • Glycogen synthase kinase-3 (GSK-3)
  • Inhibitors
  • Insulin resistance
  • Type 2 diabetes


Dive into the research topics of 'The role of glycogen synthase kinase-3 in insulin resistance and Type 2 diabetes'. Together they form a unique fingerprint.

Cite this